CIIID response to COVID-19 and the SARS-CoV-2 pandemic

CIIID investigators are collaborating with local and international colleagues in the response to the SARS-CoV-2 pandemic. These activities include directing the laboratory analysis to assess the efficacy of the Moderna vaccine across clinical trials in efforts that have now facilitated the US FDA and CDC approval of this vaccine for emergency use to vaccinate the American population and international populations.  

We have also:

• Developed a SARS-CoV-2/COVID-19 vaccine that can provide protective immunity after a single administration; this vaccine is entering clinical development.
• Determined that protective immunity develops and persists in people after infection and mild COVID-19 symptoms.
• Demonstrated the efficacy of ACE2 decoy molecules to bind SARS-CoV-2 and block infection as therapeutic applications to prevent and treat infection
• Defined single and two-tiered screening procedures for evaluating neutralizing antibody immunity to SARS-CoV-2

Current CIIID activities include defining the protective innate immune response and innate immune genes that control SARS-CoV-2/COVID-19, and determining the human and viral-genetic features of remdesivir sensitivity, innate immune regulation and resistance, and immune response  sensitivity to infection. Our biomedical professionals are working around the clock to combat the SARS-COV-2/COVID-19 pandemic.